Hikma Pharmaceuticals PLC HIK.L · Stock Open Hikma Pharmaceuticals PLC in new tab
Hikma Pharmaceuticals PLC Analysis (HIK.L)
Is Hikma Pharmaceuticals PLC a good investment? Hikma Pharmaceuticals PLC (HIK.L) is currently trading at 1548.00 GBX. Market analysts have a consensus price target of 1920.45 GBX. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 11.03. This relatively low multiple may signal that Hikma Pharmaceuticals PLC is undervalued compared to historical market norms.
Earnings Schedule: Hikma Pharmaceuticals PLC is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 1.89.
For income investors, Hikma Pharmaceuticals PLC pays a dividend yield of 4.05%. With a payout ratio of 45%, the dividend appears sustainable.
Investor FAQ
Does Hikma Pharmaceuticals PLC pay a dividend?
Yes, it pays an annual dividend of 0.82 GBX (4.05% yield).
What asset class is Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 1.38.
Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
| Year | Total Dividends |
|---|---|
| ▸2027 |
39.58 GBX
|
| April 26, 2027 (estimated) | 39.5804 |
| ▸2026 |
67.05 GBX
|
| Sept. 21, 2026 (estimated) | 31.7533 |
| April 30, 2026 | 35.2920 |
| ▸2025 |
63.52 GBX
|
| Sept. 18, 2025 | 26.5062 |
| May 1, 2025 | 37.0142 |
| ▸2024 |
62.04 GBX
|
| Sept. 20, 2024 | 24.8979 |
| May 3, 2024 | 37.1432 |
| ▸2023 |
49.66 GBX
|
| Sept. 15, 2023 | 19.6317 |
| May 5, 2023 | 30.0288 |
| ▸2022 |
43.19 GBX
|
| Sept. 20, 2022 | 15.8281 |
| April 28, 2022 | 27.3608 |
| ▸2021 |
37.57 GBX
|
| Sept. 20, 2021 | 13.1762 |
| April 26, 2021 | 24.3964 |
| ▸2020 |
37.91 GBX
|
| Sept. 21, 2020 | 12.1775 |
| May 7, 2020 | 25.7279 |
| ▸2019 |
31.30 GBX
|
| Sept. 23, 2019 | 11.4267 |
| May 22, 2019 | 19.8777 |
| ▸2018 |
25.78 GBX
|
| Sept. 21, 2018 | 9.3494 |
| May 24, 2018 | 16.4333 |
| ▸2017 |
26.20 GBX
|
| Sept. 22, 2017 | 8.5948 |
| May 25, 2017 | 17.6049 |
| ▸2016 |
22.92 GBX
|
| Sept. 1, 2016 | 8.4498 |
| April 7, 2016 | 14.4728 |
| ▸2015 |
20.45 GBX
|
| Aug. 27, 2015 | 7.1364 |
| April 16, 2015 | 13.3110 |
| ▸2014 |
16.80 GBX
|
| Aug. 27, 2014 | 6.6000 |
| April 23, 2014 | 10.2000 |
| ▸2013 |
12.96 GBX
|
| Sept. 4, 2013 | 6.2580 |
| April 17, 2013 | 6.7000 |
| ▸2012 |
8.29 GBX
|
| Aug. 29, 2012 | 3.6940 |
| April 18, 2012 | 4.6000 |
| ▸2011 |
8.16 GBX
|
| Sept. 7, 2011 | 3.5550 |
| April 13, 2011 | 4.6000 |
| ▸2010 |
8.00 GBX
|
| Sept. 8, 2010 | 3.6000 |
| April 14, 2010 | 4.4000 |
| ▸2009 |
5.55 GBX
|
| Sept. 16, 2009 | 2.7500 |
| April 29, 2009 | 2.8000 |
| ▸2008 |
3.90 GBX
|
| Sept. 17, 2008 | 1.9000 |
| April 30, 2008 | 2.0000 |
| ▸2007 |
3.80 GBX
|
| Sept. 26, 2007 | 1.7000 |
| May 16, 2007 | 2.1000 |
| ▸2006 |
2.10 GBX
|
| Sept. 27, 2006 | 1.6000 |
| April 26, 2006 | 0.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Hikma Pharmaceuticals PLC | Apr 30, 2026 | Paid | 35.292 GBX |
| Hikma Pharmaceuticals PLC | Sep 18, 2025 | Paid | 26.50615 GBX |
Community Discussion